antneoplastic chemotherapy
Order by
32 terms
Terms | Definitions |
|---|---|
oncogenes | genes when mutated become constitutively active, and thus lead to cancer*often involved in signal transduction pathways |
tumor suppressors | genes when mutated become inactive, thus lead to cancer*often involved in check point controls |
minimum of four oncogenes or tumor suppressor genes must be mutated in the same cell | minimum of four oncogenes or tumor suppressor genes must be mutated in the same cell |
selective toxicity | oncogenes: design drugs that prefer the mutated formtumor suppressors: if we damage cancer cells, they won't have the mechanisms to stop and repair damage before progressing through cell cycle |
class 1 agents | -exert effects on all cells both proliferating and on-proliferating -kill both normal and malignant cells to same extent |
class 2 agents | -cell cycle specific-target proliferating cells in preference to resting cells -will kill only cells in one specific phase of the cell cycle |
class 3 agents | -cell cycle phase non-specific-kill proliferating cells in preference to resting cell |
key points of resistance | MOR: 1) mutation on target proteins which lower the affinity of the drug for its target2) up-regulation of proteins which can counter the effects of chemotherapeutic drug **consider the dosing schedule: given time off for normal cells to recover = ideal for resistance |
antimetabolites/DNA synthesis inhibitors | -folate antagonists-purine antagonists -pyrimidine antagonists -ribnucleotide reductase inhbitors **affect cancer cells in S phase |
methotrexate | -folate antagonistMOA: inhibits DHFR -class 2 (S phase) Toxicitie: -myelosupression -mucositis -renal failure |
thioguanine | -purine antagonist-MOA: class 2 (S) -requires activation -inhibts PRPP |
5-fluorouracil | -pyrimidine antagonistMOA: class 2 (S) -requires bioactivation by THF -**inhibits thymidylate synthase -toxicities: myelosupression, hand-foot syndrome, cardiac symptoms of chest pain |
hydroxyurea | -ribonucleotide reductase inhibitor-DNA cannot be formed from RNA |
DNA alkylating drugs | -MOA: class 3 (cell-cycle nonspecific)-bind to DNA and cause cross-links -includes mustard gas |
leucovorin | -basically folic acid-given if folate antagonist toxicities become too significant |
topotecan | -blocks topoisomerase I from RELIGATING the DNA after single strand breakshave been made |
etoposide | -allows topo II to create double strand breaks, but prevents unwinding, and thus religation |
doxorubicin | -DNA intercalating drug-MOA: fits into DNA grooves, some converted to free-radicals-causing single and double stranded DNA breaks |
vincristine | -MOA: inhibits tubulin polymerization into microtubules-toxicities: neurotoxic |
paclitaxel | MOA: enhances polymerization and blocks depolymerization of microtubules-toxicity: neurotoxic, hypersensitivity |
rituximab | anti-CD20 |
trastuzumab | anti-HER2/neu |
bevacizumab | anti-VEGF |
panitumumab | anti EGF receptor |
moa of monoclonal antibodies | 1)opsonization2)inhibition of function 3)for growth factor receptors - blockng of dimerization |
imatinib | -tyrosine kinase inhibitor-Bcr-abl |
erlotinib | -tyrosine kinase inhibitor-EGF receptor |
bortezimid | MOA: inhibits 26S proteasome which is used to degrade proteins that have been ubiquinated-toxicities: infusion reactions, neuropathies |
inteferons | MOA: differentiation of tumor cells, changes in gene expression, changes in phosphorylation patterns-Toxicities: flu-like symptoms |
growth factors | MOA: stimulates growth of specific blood cells to help combat bone marrow suppression*these drugs help with the adverse symptoms of chemo |
tamoxifen | MOA: blocks binding of estrogen to estrogen receptortoxicity: menapausal symptoms, masculinization |
flutamide | MOA: inhibits bindng of testosterone to androgen receptortoxicity: hot flashes, gynecomastia, nipple pain, glactorrhea, feminization, impotence |
First Time Here?
Welcome to Quizlet, a fun, free place to study. Try these flashcards, find others to study, or make your own.